아이엠비디엑스

461030KOSDAQ

55.3 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IMBIX is a global healthcare company leading the way in precision cancer diagnosis and early detection using liquid biopsy and next-generation sequencing (NGS) technologies. Its core business areas include precision diagnosis of advanced cancers, early detection of post-surgical recurrence, and early cancer screening, supported by products like AlphaLiquide®100 and HRR.

Number of Employees

65people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.62Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-27.54Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

1.67Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲56.4% (1-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.4% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -37.3% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
아이엠비디엑스, 정부 사업 통해 50억원 확보…중장기 투자 재원
아이엠비디엑스가 정부 지원 사업을 통해 대규모 자금을 확보하여 중장기 투자에 유리한 조건을 얻었다.
Positive
아이엠비디엑스, 캔서파인드 암종 30개까지 확대…“보급형 연계로 시.....
아이엠비디엑스의 캔서파인드 MCED 검사 범위 확대 및 보급형 제품 출시로 인해 암 조기진단 시장에서의 경쟁력 강화가 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 2,845Won52-week high 12,08052-week low 2,595

1-month return1.0Point

1m -13.79% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14